Viewing Study NCT00179686



Ignite Creation Date: 2024-05-05 @ 11:55 AM
Last Modification Date: 2024-10-26 @ 9:16 AM
Study NCT ID: NCT00179686
Status: COMPLETED
Last Update Posted: 2006-12-20
First Post: 2005-09-10

Brief Title: A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer
Sponsor: Celgene Corporation
Organization: Celgene

Study Overview

Official Title: A Multicenter Single-Arm Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide Revlimid CC-5013 in Subjects With Recurrent Non-Small Cell Lung Cancer
Status: COMPLETED
Status Verified Date: 2006-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Subjects who qualify will receive single agent lenalidomide once daily on days 1-21 of 28 day cycles Subjects will continue until disease progression is documented
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None